Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus, and available under a different brand for weight management in eligible adults. Whilst the medication typically reduces appetite and food cravings through its action on satiety pathways, some patients report experiencing increased cravings for sweet foods during treatment. This article explores why craving sweets on Mounjaro may occur, the physiological and behavioural mechanisms that might contribute to this response, and practical strategies for managing sugar cravings whilst maintaining effective glycaemic control and supporting your treatment goals.

How Mounjaro Affects Appetite and Food Cravings

Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. In the UK, it is licensed for the treatment of type 2 diabetes mellitus. Tirzepatide is also available under a different brand name for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, subject to specific NHS commissioning criteria.

The medication works by mimicking naturally occurring incretin hormones that regulate blood glucose levels and appetite. Through its action on both GIP and GLP-1 receptors, tirzepatide influences multiple pathways involved in glucose and appetite regulation.

Mounjaro affects appetite primarily by activating receptors in the brain, particularly in areas that control satiety and food intake. By stimulating GLP-1 receptors in the hypothalamus and brainstem, tirzepatide slows gastric emptying (though this effect may diminish over time), prolongs the feeling of fullness after meals, and reduces hunger signals. Many patients report decreased appetite and food cravings within the first few weeks of treatment.

Clinical trials have shown that tirzepatide reduces body weight, with results varying by dose and patient population. In people with obesity without diabetes (SURMOUNT-1 trial), higher doses achieved weight loss of up to 20% over 72 weeks, while in type 2 diabetes (SURPASS trials), the weight loss was typically lower. This weight reduction is largely attributed to decreased caloric intake resulting from appetite suppression.

While the dual action on both GIP and GLP-1 receptors appears to influence appetite regulation, individual responses vary considerably, and some patients may experience changes in their food preferences or cravings that differ from the expected pattern of reduced appetite.

Why Sweet Cravings May Occur During Mounjaro Treatment

Whilst Mounjaro typically reduces overall appetite and food cravings, some patients report experiencing increased cravings for sweet foods during treatment. This seemingly paradoxical response is not well documented in the formal literature, and several physiological and behavioural mechanisms have been proposed to explain this phenomenon, though these remain largely hypothetical.

One potential explanation relates to changes in blood glucose regulation. As Mounjaro improves glycaemic control and reduces blood sugar fluctuations, some individuals—particularly those with previously poorly controlled diabetes—may experience what feels like relative hypoglycaemia even when blood glucose remains within the normal range. The body may interpret this change as a signal to seek quick energy sources, potentially manifesting as cravings for sugary foods. It's important to note that true hypoglycaemia with Mounjaro monotherapy is uncommon; the risk increases mainly when used with insulin or sulphonylureas.

Another hypothesis involves altered taste perception and food preferences. Some research suggests GLP-1 receptor agonists may influence taste sensitivity and food reward pathways in the brain. Some patients report that previously appealing savoury or fatty foods become less palatable, which could theoretically shift preferences towards other options, including sweeter foods. Additionally, the significant reduction in overall food intake may lead to energy deficits, prompting the body to seek calorie-dense foods.

Psychological factors may also play a role. Patients who experience nausea or food aversions—common side effects of Mounjaro—may find that sweet foods are more tolerable. Furthermore, restrictive eating patterns or the stress of dietary changes may trigger cravings as a compensatory response. It is important to note that there is no established link between Mounjaro and increased sweet cravings specifically, and individual experiences vary widely.

Managing Sugar Cravings While Taking Mounjaro

Effectively managing sweet cravings whilst taking Mounjaro requires a combination of dietary strategies, lifestyle modifications, and awareness of nutritional needs. The goal is to maintain stable blood glucose levels, ensure adequate nutrition, and support the medication's therapeutic effects.

Dietary approaches should focus on consuming regular, balanced meals that include adequate protein, healthy fats, and complex carbohydrates. Protein-rich foods help promote satiety and stabilise blood sugar levels, reducing the likelihood of reactive cravings. Including fibre from vegetables, whole grains, and legumes slows glucose absorption and provides sustained energy. When sweet cravings occur, consider healthier alternatives such as fresh fruit, Greek yoghurt with berries, or small portions of dark chocolate, being mindful that even these healthier options contain calories that count towards your daily intake.

Hydration is often overlooked but essential, as dehydration can sometimes be misinterpreted as hunger or cravings. Aim for adequate fluid intake throughout the day, primarily from water, and limit sugary beverages that can exacerbate blood glucose fluctuations.

Monitoring portion sizes remains important even when cravings occur. Mounjaro's appetite-suppressing effects mean that overall caloric intake is typically reduced, but consuming large amounts of sugary foods can counteract weight loss efforts and affect glycaemic control. Mindful eating practices—eating slowly, without distractions, and paying attention to hunger and fullness cues—can help distinguish between genuine hunger and habitual or emotional cravings.

If you're experiencing symptoms of hypoglycaemia (shakiness, sweating, confusion), it is appropriate to use fast-acting carbohydrates like glucose tablets or fruit juice according to NHS guidance.

If cravings persist or interfere with diabetes management or weight loss goals, consider asking your GP for a referral to an NHS-registered dietitian who can provide personalised nutritional guidance tailored to your treatment plan and metabolic needs. NHS structured education programmes for diabetes, such as DESMOND, may also provide helpful strategies.

When to Speak to Your GP About Cravings on Mounjaro

Whilst occasional sweet cravings during Mounjaro treatment are generally not cause for concern, certain situations warrant discussion with your GP or diabetes specialist nurse. Recognising when cravings may indicate an underlying issue is important for optimising treatment outcomes and ensuring patient safety.

You should contact your GP if you experience symptoms of hypoglycaemia alongside sweet cravings, particularly if you are taking Mounjaro in combination with other diabetes medications such as sulphonylureas or insulin. Warning signs include trembling, sweating, confusion, dizziness, palpitations, or feeling unusually hungry. These symptoms may indicate that your diabetes medication regimen requires adjustment to prevent low blood sugar episodes. Note that when starting Mounjaro, doses of insulin or sulphonylureas may need to be reduced to avoid hypoglycaemia.

Persistent or overwhelming cravings that interfere with your ability to maintain a healthy diet or that lead to significant consumption of sugary foods should also be discussed. This is especially important if you notice that your blood glucose control is deteriorating, as reflected in home monitoring readings or HbA1c levels. Your healthcare provider may need to review your treatment plan, adjust your Mounjaro dose, or assess whether other factors are contributing to poor glycaemic control.

Additionally, if sweet cravings are accompanied by other concerning symptoms such as unexplained weight gain (despite being on Mounjaro), persistent nausea or vomiting, severe abdominal pain, or signs of pancreatitis, seek medical advice promptly. For severe, persistent abdominal pain (especially if radiating to the back) with vomiting, seek urgent same-day medical attention or go to A&E, as this could indicate pancreatitis, a rare but serious potential side effect.

Finally, if you suspect that cravings may be related to disordered eating patterns or psychological factors, discussing this with your GP can facilitate appropriate referrals to mental health services or specialist eating disorder support. Managing diabetes and weight requires a holistic approach that addresses both physical and psychological wellbeing.

If you experience any suspected side effects from Mounjaro, these can be reported through the MHRA Yellow Card scheme.

Blood Sugar Levels and Sweet Cravings on Mounjaro

Understanding the relationship between blood glucose levels and sweet cravings is fundamental for patients taking Mounjaro, particularly those with type 2 diabetes. The medication's mechanism of action directly influences glucose homeostasis, which in turn can affect appetite regulation and food preferences.

Mounjaro works by enhancing glucose-dependent insulin secretion from pancreatic beta cells and suppressing inappropriate glucagon release from alpha cells. This dual action helps maintain blood glucose within target ranges, reducing both hyperglycaemia after meals and fasting glucose levels. For many patients, especially those transitioning from poor glycaemic control, this represents a significant physiological adjustment. The body's glucose-sensing mechanisms, which have adapted to chronically elevated blood sugar levels, may initially interpret normal or improved glucose levels as relatively low, potentially triggering hunger signals and cravings for quick-acting carbohydrates.

Blood glucose monitoring may be helpful in certain circumstances, particularly if you are taking Mounjaro alongside insulin or sulphonylureas, which increase the risk of hypoglycaemia. In line with NICE guidance, routine self-monitoring of blood glucose is not generally recommended for people with type 2 diabetes who are not using insulin or medications that can cause hypoglycaemia. However, if you experience symptoms that could indicate low blood sugar coinciding with sweet cravings, checking your glucose levels can provide valuable information.

NICE guidelines recommend individualised glycaemic targets. For most adults with type 2 diabetes, an HbA1c target of 48 mmol/mol (6.5%) is appropriate if achievable without causing problematic hypoglycaemia. For those on insulin or sulphonylureas, a slightly higher target of 53 mmol/mol (7.0%) may be more appropriate to reduce hypoglycaemia risk. Your healthcare team will set personalised targets based on your specific circumstances.

As your body adjusts to improved glycaemic control and the appetite-regulating effects of Mounjaro, many patients find that cravings—including those for sweet foods—may diminish. Maintaining consistent meal timing, avoiding prolonged periods without food, and ensuring adequate complex carbohydrate intake can help prevent the blood sugar fluctuations that may trigger cravings. If you have concerns about the relationship between your blood glucose patterns and food cravings, discuss monitoring strategies and interpretation with your diabetes care team.

Frequently Asked Questions